MCM
CPRX

Matarin Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Matarin Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-64,411
Closed -$248K – 200
2020
Q1 		$248K Buy
+64,411
New +$264K 0.04% 196

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Matarin Capital Management's CPRX Position: Q2 2020 in Review

Matarin Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2020, closing a stake of 64,411 shares — an estimated $248K sold.

Matarin Capital Management first reported a position in CPRX in Q1 2020 and held it in 1 quarter. The position peaked at $248K in Q1 2020. 140 funds tracked by Wall St. Rank hold CPRX as of Q2 2020.

  • Matarin Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2020 after selling out during the quarter.
  • Matarin Capital Management sold 64,411 Catalyst Pharmaceutical shares in Q2 2020, an estimated $248K.
  • Matarin Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2020 and held it in 1 quarter.
  • Matarin Capital Management's Catalyst Pharmaceutical position peaked at $248K in Q1 2020.
  • 140 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2020.

Based on Matarin Capital Management's 13F filing for Q2 2020, filed 6 Aug 2020.